Xspray Pharma AB (publ) (STO:XSPRAY)

Sweden flag Sweden · Delayed Price · Currency is SEK
25.60
-0.60 (-2.29%)
At close: Mar 2, 2026
Market Cap1.09B -5.3%
Revenue (ttm)n/a
Net Income-171.44M
EPS-4.46
Shares Out41.74M
PE Ration/a
Forward PE2.18
Dividendn/a
Ex-Dividend Daten/a
Volume15,251
Average Volume27,268
Open26.20
Previous Close26.20
Day's Range25.15 - 26.75
52-Week Range23.00 - 64.10
Beta0.07
RSI46.55
Earnings DateFeb 12, 2026

About Xspray Pharma AB

Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer; and XS025, a amorphous non-crystalline cabozantinib for the treatment of renal cell carcinoma and other cancers. It has partn... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 26
Stock Exchange Nasdaq Stockholm
Ticker Symbol XSPRAY
Full Company Profile

Financial Performance

Financial Statements